Neurocrine Biosciences | 営業利益

株価
131.14
毎日の変更
0.18 0.14%
毎月
-2.51%
毎年
11.52%
Q1 予測
124.64




営業利益 変化する 日付
AbbVie USD 5.81B 1.23B 2025-12
Acadia Pharmaceuticals USD 35.76M 3.38M 2025-09
Agios Pharmaceuticals USD -121.58M 4.71M 2025-12
ALKERMES USD -10.95M 100.03M 2025-12
Alnylam Pharmaceuticals USD 29.4M 59.36M 2025-12
Amgen USD 3.96B 464M 2025-12
Biogen USD 659.6M 192.2M 2025-09
BioMarin Pharmaceutical USD 198.39M 230.08M 2025-12
Cytokinetics USD -178.37M 11.61M 2025-12
Enanta Pharmaceuticals USD -23.54M 98.15M 2024-12
Exelixis USD 235.91M 20.45M 2025-12
Gilead Sciences USD 2.96B 551M 2025-12
Halozyme Therapeutics USD -88.41M 306.33M 2025-12
Incyte USD 383.88M 47.43M 2025-12
Ionis Pharmaceuticals USD -215M 54.82M 2025-12
Nektar Therapeutics USD -34.34M 15.43M 2024-09
Neurocrine Biosciences USD 227.9M 11.4M 2025-12
Pfizer USD 4.65B 3.99B 2025-12
Prothena USD -39.76M 12.25M 2025-09
Regeneron Pharmaceuticals USD 898.6M 211.3M 2025-12
Repligen USD 19.97M 7.29M 2025-12
Rigel Pharmaceuticals USD 14.06M 13.61M 2024-09
Sarepta Therapeutics USD -62.88M 178.46M 2025-09
Teva Pharmaceutical Industries USD 487M 581M 2025-12
Ultragenyx Pharmaceutical USD -114M 56.89M 2025-12
Vertex Pharmaceuticals USD 1.26B 24.5M 2025-12
Xoma USD -15.64M 5.56M 2024-09


Neurocrine Biosciences 営業利益 - 現在の値は、過去のデータ、予測、統計、チャートや経済カレンダー - Feb 2026.